MedTrace Logo

Swedish Ibrance Registries Insights (SIRI)

NCT04654208 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-03-31

No results posted yet for this study

Summary

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Conditions

  • Malignant Neoplasm of Breast

Interventions

DRUG

palbociclib

patients on palbociclib combination treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04654208 on ClinicalTrials.gov